Insurance companies will be less likely to buy CMBS AMs and yieldier dupers at a premium.

This is because these securities might be capped at book prices at around par under the recently revised National Association of Insurance Commisioners (NAIC) capital treatment requirements, said Scott Buchta, head of investment strategy at Braver Stern Securities.

Subscribe Now

Access to a full range of industry content, analysis and expert commentary.

30-Day Free Trial

No credit card required. Access coverage of the securitization marketplace, including breaking news updated throughout the day.